Morgan Lewis advised Yokogawa Electric Corp. in the transaction.
Yokogawa Electric Corporation (TOKYO: 6841) executed the acquisition of a nanopipette technology that was developed by BioStinger, Inc., a spin-off from the University of California, Santa Cruz.
This technology is able to target specific locations inside individual cells, enabling the injection of target substances such as genes or drugs and the extraction of intracellular materials. The low invasiveness of this technology to cells enables more detailed analysis of live single cells, organelles, and cytoplasmic components.
Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper.
Founded in 2014, BioStinger is a corporation that was founded by Professor Nader Pourmand, who is a leading authority in single-cell analysis, and other academics.
Morgan Lewis team advising Yokogawa was led by partners Nancy Yamaguchi, Karen Abesamis, and Rahul Kapoor, while partners Ken Nunnenkamp and Giovanna Cinelli led on Committee on Foreign Investment in the United States (CFIUS) matters.
Law Firms: Morgan Lewis;
Clients: Yokogawa Electric Corporation;